![]() LUMABS sensors with physiologically relevant affinities and decent sensor responses were obtained for trastuzumab and cetuximab using mimotope and meditope peptides, respectively, with affinities in the 10 –7 M range. A strong correlation was found between the affinity of the antibody binding peptide and sensor performance. In this study, we targeted four clinically important therapeutic antibodies, the Her2-receptor targeting trastuzumab, the anti-CD20 antibodies rituximab and obinutuzumab, and the EGFR-blocking cetuximab. ![]() Our group recently developed a new platform of bioluminescent sensor proteins (LUMABS LUMinescent AntiBody Sensor) that allow antibody detection directly in blood plasma. Monitoring the levels of therapeutic antibodies in individual patients would allow patient-specific dose optimization, with the potential for major therapeutic and financial benefits.
0 Comments
Leave a Reply. |